HC
INBX icon

Hurley Capital’s Inhibrx INBX Stock Holding History

Hurley Capital’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,660
Closed -$131K – 718
2025
Q4 		$131K Buy
+1,660
New +$113K 0.07% 106

Other funds holding INBX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Hurley Capital's INBX Position: Q1 2026 in Review

Hurley Capital sold out of Inhibrx (INBX) in Q1 2026, closing a stake of 1,660 shares — an estimated $131K sold.

Hurley Capital first reported a position in INBX in Q4 2025 and held it in 1 quarter. The position peaked at $131K in Q4 2025. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

  • Hurley Capital reported no remaining Inhibrx position as of Q1 2026 after selling out during the quarter.
  • Hurley Capital sold 1,660 Inhibrx shares in Q1 2026, an estimated $131K.
  • Hurley Capital first reported a position in Inhibrx in Q4 2025 and held it in 1 quarter.
  • Hurley Capital's Inhibrx position peaked at $131K in Q4 2025.
  • 135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on Hurley Capital's 13F filing for Q1 2026, filed 6 May 2026.